Treatment for aggressive form of prostate cancer may be on horizon

A drug tested unsuccessfully in patients with prostate cancer may actually benefit patients who suffer from neuroendocrine prostate tumors, a particularly lethal form of the disease. Weill Cornell Medical College researchers and others found that the aurora kinase inhibitor PHA-739358 appeared to work well against human neuroendocrine prostate cells in the lab. The drug also shrank neuroendocrine tumors in mice. Details are published in the latest issue of the journal Cancer Discovery. Release

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.